Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06851663 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Trop2-targeted immunoPET Imaging of Solid Tumors

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints: 4 to 5
    • Study description expanded, about 16 words
    v4
  2. Phase: Not applicable to Phase 2/3v3
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
RenJi Hospital
190 trials monitored
See 2 trials at risk
Lung Cancer
4,790 trials monitored
See 263 trials at risk
Head & Neck Cancer
2,605 trials monitored
See 150 trials at risk
Prostate Cancer
2,546 trials monitored
See 172 trials at risk
and 7 more diseases
This study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging method and its physiological and pathological distribution characteristics, based on which the diagnostic efficacy of the above imaging agents in solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) will be evaluated.
Trial Details
NCT Number NCT06851663
Lead Sponsor RenJi Hospital
Conditions
(from sponsor)		 Solid Tumor, Solid Carcinoma, Uroepithelial Carcinoma, Bladder Cancer, Prostate Cancer, Lung Cancer, Nasopharyngeal Cancer, Liver Cancer +6 more
Related terms Carcinoma, Transitional Cell, Cholangiocarcinoma, Endometrial Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Nasopharyngeal Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Thyroid Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov